Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cidara Therapeutics

21.50
-0.1900-0.88%
Pre-market: 21.680.1800+0.84%04:32 EDT
Volume:27.29K
Turnover:590.25K
Market Cap:269.75M
PE:-0.80
High:22.00
Open:21.55
Low:21.22
Close:21.69
Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

Cidara Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
07 Mar

Cidara Therapeutics reports Q4 EPS ($5.37) vs. (71c) last year

TIPRANKS
·
07 Mar

Cidara Therapeutics Q4 2024 GAAP EPS $(5.37) Misses $(3.62) Estimate

Benzinga
·
07 Mar

BRIEF-Cidara Therapeutics Announces Appointment Of Frank Karbe As Chief Financial Officer

Reuters
·
19 Feb

Cidara Therapeutics Inc - Preetam Shah Departs as CFO of Cidara Therapeutics

THOMSON REUTERS
·
19 Feb

Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

THOMSON REUTERS
·
19 Feb

Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

GlobeNewswire
·
19 Feb

Cidara Therapeutics Coverage Assumed by Cantor Fitzgerald at Overweight

Dow Jones
·
27 Jan

Here’s Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing

Insider Monkey
·
14 Jan

Cidara Therapeutics Announces Leadership Changes and Appointments

TIPRANKS
·
08 Jan

Cidara Therapeutics Files Secondary Stock Sale Statement

MT Newswires Live
·
24 Dec 2024

Cidara Therapeutics files to sell 7.04M shares of common stock for holders

TIPRANKS
·
24 Dec 2024

Cidara Therapeutics Initiated at Outperform by RBC Capital

Dow Jones
·
13 Dec 2024

RBC Initiates Cidara Therapeutics at Outperform, Speculative Risk, With $34 Price Target

MT Newswires Live
·
13 Dec 2024

Venrock Healthcare Capital Partners Iii Lp Reports 9.99% Passive Stake in Cidara Therapeutics Inc as of November 26 - SEC Filing

THOMSON REUTERS
·
05 Dec 2024

Cidara Therapeutics completes enrollment of Phase 2b NAVIGATE trial

TIPRANKS
·
04 Dec 2024

Cidara Therapeutics Completes Enrollment of Phase 2B Navigate Trial Evaluating Cd388 for Prevention of Seasonal Influenza

THOMSON REUTERS
·
04 Dec 2024

Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza

GlobeNewswire
·
04 Dec 2024

Tcg Crossover Gp Ii, Llc Reports 9.2% Passive Stake in Cidara Therapeutics Inc as of Nov 26 - SEC Filing

THOMSON REUTERS
·
04 Dec 2024